DPYSL5 and prostate cancer: Next, to assess the expression of DPYSL5 protein in treatment-resistant patient tumors, we constructed a CRPC-t-NEPC-like tissue microarray (TMA) comprising 135 prostate cancer patient tissue samples with untreated (n = 37), CRPC/transurethral resection of the prostate (TURP) (n = 43), and t-NEPC-like (n = 55) samples.